Validating Hemagglutination Inhibition Assay For Quantifying Antibody Against Influenza A/H5n1, And Detecting Maintenance Of Antibody Against Influenza A/H5n1 In Vaccinated Human Serum

Abstract

Influenza is a common disease and spread via the respiratory tract, so it spreads very quickly and easily becomes a pandemic. Vietnam is one of the first countries to record a highly pathogenic avian influenza (HPIA) infection. Human cases of H5N1 avian influenza occur occasionally, but it is difficult to transmit the infection from person to person. When people do become infected, the mortality rate is about 60%. The hemagglutination inhibition assay is used to titrate the antibody response to a viral infection. The hemagglutination inhibition assay takes advantage of H5N1 Influenza viruses' ability to hemagglutinate red blood cells, therefore forming a "lattice" and preventing the red blood cells from clumping. Two main parts that will be focused on this thesis validate the hemagglutination inhibition assay and detecting the amount of H5N1 antibody after getting being vaccinated with Ivacflu A/H5N1. The results of the research show that the hemagglutination inhibition assay meets the set standards when performed at IVAC. The results also showed that there is a clear difference in the maintenance of serum antibody levels after 2 years and 3 years of vaccinated.